Unique ID issued by UMIN | UMIN000025501 |
---|---|
Receipt number | R000029350 |
Scientific Title | Exploratory study of adverse events at the unexperienced hospital in the treatment for gastric cancer with peritoneal metastasis with intraperitoneal paclitaxel combined with S-1 plus oxaliplatin |
Date of disclosure of the study information | 2017/02/28 |
Last modified on | 2024/07/10 14:46:46 |
Exploratory study of adverse events at the unexperienced hospital in the treatment for gastric cancer with peritoneal metastasis with intraperitoneal paclitaxel combined with S-1 plus oxaliplatin
Exploratory study of adverse events in SOX+IP PTX for peritoenal metastasis of gastric cancer
Exploratory study of adverse events at the unexperienced hospital in the treatment for gastric cancer with peritoneal metastasis with intraperitoneal paclitaxel combined with S-1 plus oxaliplatin
Exploratory study of adverse events in SOX+IP PTX for peritoenal metastasis of gastric cancer
Japan |
gastric cancer with peritoneal metastasis
Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Malignancy
NO
To evaluate the safety of intraperitoneal paclitaxel combined with S-1 plus oxaliplatin in gastric cancer patients with peritoneal metastasis at the the unexperienced hospital.
Safety
Exploratory
Phase II
safety
1-year overall survival
response rate
negative conversion rate on peritoneal cytology
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
PTX is administered intraperitoneally at 40 mg/m2 on days 1 and 8.
S-1 is administered at 80 mg/m2/day for 14 consecutive days, followed by 7 days rest.
Oxaliplatin is administered at 100 mg/m2 on day1.
20 | years-old | <= |
75 | years-old | > |
Male and Female
Histologically proven unresectable or recurrent gastric adenocarcinoma; peritoneal metastasis and/or cancer cells on peritoneal cytology; age more than 20 years; Eastern Cooperative Oncology Group performance status 0-2; adequate bone marrow function (leukocyte count 3,000-12,000/mm3, hemoglobin >8.0 g/dl, platelet count >100,000/mm3); adequate liver function (total serum bilirubin <1.5 mg/dl, serum transaminases <100/UI); adequate renal function (serum creatinine within the upper limit of normal); and an expected survival period of more than 3 months.
Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical condition.
30
1st name | Hironori |
Middle name | |
Last name | Yamaguchi |
Jichi Medical University
Department of Clinical Oncology
329-0498
3311-1 Yakushiji Shimotsukeshi Tochigi
0285-44-2111
yamaguchih-tky@umin.net
1st name | Hironori |
Middle name | |
Last name | Hironori |
Jichi Medical University
Department of Clinical Oncology
329-0498
3311-1 Yakushiji Shimotsukeshi Tochigi
0285-44-2111
yamaguchih-tky@umin.net
Jichi Medical University
Self funding
Self funding
Jichi medical university clinical research support center
3311-1 Yakushiji Shimotsukeshi Tochigi
0285-58-8933
shien@jichi.ac.jp
NO
自治医科大学附属病院(栃木県)
2017 | Year | 02 | Month | 28 | Day |
Unpublished
15
Delay expected |
Analyzing data
No longer recruiting
2017 | Year | 05 | Month | 12 | Day |
2017 | Year | 05 | Month | 10 | Day |
2017 | Year | 05 | Month | 29 | Day |
2026 | Year | 03 | Month | 31 | Day |
2017 | Year | 01 | Month | 03 | Day |
2024 | Year | 07 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029350